Yumanity Therapeutics (FRA:8IY) Days Payable : 0.00 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Days Payable?

Yumanity Therapeutics's average Accounts Payable for the three months ended in Sep. 2022 was €1.61 Mil. Yumanity Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2022 was €0.00 Mil.

The historical rank and industry rank for Yumanity Therapeutics's Days Payable or its related term are showing as below:

FRA:8IY's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.12
* Ranked among companies with meaningful Days Payable only.

Yumanity Therapeutics's Days Payable stayed the same from Sep. 2021 (0.00) to Sep. 2022 (0.00). stayed the same

Yumanity Therapeutics Days Payable Historical Data

The historical data trend for Yumanity Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Days Payable Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Days Payable

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Payable	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Yumanity Therapeutics's Days Payable

For the Biotechnology subindustry, Yumanity Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yumanity Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's Days Payable falls into.

Yumanity Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Yumanity Therapeutics's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as

	Days Payable (A: Dec. 2021 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2020 )	+	Accounts Payable (A: Dec. 2021 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2021 )	*	Days in Period
=	( (6.07	+	1.628)	/	2 )	/	0	*	365
=	3.849					/	0	*	365
=	N/A

Yumanity Therapeutics's Days Payable for the quarter that ended in Sep. 2022 is calculated as:

	Days Payable (Q: Sep. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2022 )	+	Accounts Payable (Q: Sep. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
=	( (1.513	+	1.705)	/	2 )	/	0	*	365 / 4
=	1.609					/	0	*	365 / 4
=	N/A

Yumanity Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines